Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.
Pregnant women who develop ANCA-associated vasculitis (AAV) may safely receive Rituxan (rituximab) and corticosteroids, a case study suggests. However, this is the first study describing Rituxan’s use in pregnant women with ... Read more
InflaRx will soon begin a Phase 2 clinical trial assessing the safety and effectiveness of IFX-1 — an inhibitor of the complement system — in patients with ANCA-associated vasculitis (AAV). This follows ... Read more
Some patients with ANCA-associated vasculitis (AAV) caused by hydralazine — a medication used to treat high blood pressure — develop end-stage kidney disease, even after discontinuing the medicine and receiving immunosuppressive therapy, a ... Read more
The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on to standard care for treating eosinophilic granulomatosis with polyangiitis (EGPA), previously called Churg-Strauss syndrome. “Patients suffering ... Read more
Dutch scientists have identified different genes in Staphylococcus aureus — a kind of bacteria carried in the nostrils — in either patients with PR3-ANCA vasculitis or with MPO-ANCA-positive vasculitis. The results suggest ... Read more
A review about the anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis and vasculitis outlined the best way to characterize the different kinds of ANCA-associated disease in order to provide better treatment. The review, ... Read more